<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073812441063</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073812441063</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Communication</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Nonketotic Hyperglycinemia</article-title>
<subtitle>A Cause of Encephalopathy in Children</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Veríssimo</surname>
<given-names>Carla</given-names>
</name>
<degrees>MSc</degrees>
<xref ref-type="aff" rid="aff1-0883073812441063">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Garcia</surname>
<given-names>Paula</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0883073812441063">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Simões</surname>
<given-names>Marta</given-names>
</name>
<degrees>BSc</degrees>
<xref ref-type="aff" rid="aff1-0883073812441063">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Robalo</surname>
<given-names>Conceição</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0883073812441063">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Henriques</surname>
<given-names>Raquel</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0883073812441063">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Diogo</surname>
<given-names>Luísa</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-0883073812441063">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Grazina</surname>
<given-names>Manuela</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0883073812441063">1</xref>
<xref ref-type="aff" rid="aff4-0883073812441063">4</xref>
<xref ref-type="corresp" rid="corresp1-0883073812441063"/>
</contrib>
</contrib-group>
<aff id="aff1-0883073812441063">
<label>1</label>Centro de Neurociências e Biologia Celular, Universidade de Coimbra, Laboratório de Bioquímica Genética, Coimbra, Portugal</aff>
<aff id="aff2-0883073812441063">
<label>2</label>Unidade de Doenças Metabólicas, Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal</aff>
<aff id="aff3-0883073812441063">
<label>3</label>UCIRN-Maternidade Daniel de Matos, Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal</aff>
<aff id="aff4-0883073812441063">
<label>4</label>Faculdade de Medicina, Universidade de Coimbra, Azinhaga de Santa Comba, Coimbra, Portugal</aff>
<author-notes>
<corresp id="corresp1-0883073812441063">Manuela Grazina, PhD, Faculdade de Medicina de Coimbra, Universidade de Coimbra, Pólo III–Subunidade I de Ensino, 2° andar, Gab. 2.31, Azinhaga de Sta Comba Celas, 3000-354 Coimbra, Portugal. Email: <email>mmgrazina@gmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>2</issue>
<fpage>251</fpage>
<lpage>254</lpage>
<history>
<date date-type="received">
<day>31</day>
<month>1</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>2</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Nonketotic hyperglycinemia is a rare metabolic disorder with severe, frequently fatal, neurologic manifestations. Reliable and accurate diagnosis depends on careful interpretation of laboratory findings. The clinical suspicion should lead to determination of glycine in plasma and cerebrospinal fluid. Amino acid analysis presents diagnostic values for classic nonketotic hyperglycinemia, but it also should be performed in suspected cases of atypical nonketotic hyperglycinemia and in children with seizures, failure to thrive, behavior problems, and uncoordinated movements. Clinical assessment should be reinforced by demonstration of elevated cerebrospinal fluid–to–plasma glycine ratio. Confirmatory diagnosis requires enzymatic and genetic investigation of glycine cleavage system. An early diagnosis, though not affecting clinical outcome, allows proper genetic counseling, with the possibility of prenatal diagnosis. We report 3 cases of nonketotic hyperglycinemia, 2 typical neonatal and 1 atypical, diagnosed in Pediatric Hospital of Coimbra, Portugal, and investigated at Laboratory of Biochemical Genetics in 2004 to 2010 (incidence 1:47 455; prevalence 1:782 951).</p>
</abstract>
<kwd-group>
<kwd>glycine</kwd>
<kwd>ion exchange chromatography</kwd>
<kwd>nonketotic hyperglycinemia</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Glycine encephalopathy or nonketotic hyperglycinemia (NKH; OMIM no. 605899) is an inborn error of glycine metabolism, leading to its accumulation in all body tissues, especially the central nervous system. It is caused by a biochemical defect in the glycine cleavage system.<sup><xref ref-type="bibr" rid="bibr1-0883073812441063">1</xref></sup> This system is a multipeptide enzymatic system located in the inner mitochondrial membrane of the brain, liver, kidney, and placental cells, which catalyzes both the synthesis and the oxidative cleavage of glycine to CO<sub>2</sub>, NH<sub>4</sub><sup>+</sup>, and a methylene group, accepted by tetrahydrofolate. It plays an important role in the metabolism of one carbon unit, namely, in the biosynthesis of several cellular substances such as purines, thymidylate, and methionine.<sup><xref ref-type="bibr" rid="bibr2-0883073812441063">2</xref></sup>
</p>
<p>The glycine cleavage system is formed by 4 proteins, P, H, T, and L, which are encoded by <italic>GLDC</italic>, <italic>GCSH</italic>, <italic>AMT</italic>, and <italic>GCSL</italic> genes, respectively.</p>
<p>Nonketotic hyperglycinemia is inherited as an autosomal recessive trait. It is considered a rare disorder, but the exact worldwide incidence is not known. A high incidence of nonketotic hyperglycinemia has been reported in certain ethnic groups and geographic locations. In Finland, the incidence is 1:55 000 newborn babies, but it is even higher in northern Finland, with an incidence of 1:12 000.<sup><xref ref-type="bibr" rid="bibr3-0883073812441063">3</xref></sup> In British Columbia, Canada, it is 1:63 000, also probably higher than the expected worldwide incidence.<sup><xref ref-type="bibr" rid="bibr4-0883073812441063">4</xref></sup>
</p>
<p>Most patients have the classic form, clinical presentation in the neonatal period, with lethargy, hypotonia, and apnea. The disease progresses to coma and death usually in the first 6 months of life or leads to epileptic encephalopathy, with profound mental retardation.<sup><xref ref-type="bibr" rid="bibr1-0883073812441063">1</xref>,<xref ref-type="bibr" rid="bibr3-0883073812441063">3</xref></sup> Unlike the classic neonatal form, atypical forms present with heterogeneous and nonspecific phenotype, making diagnosis more difficult to achieve.<sup><xref ref-type="bibr" rid="bibr5-0883073812441063">5</xref></sup> Another type, transient nonketotic hyperglycinemia, is characterized by elevated levels of glycine at birth, in plasma and cerebrospinal fluid, partially or completely resolved in a period ranging from days to months. The biochemical and clinical observations are similar to those found in classic nonketotic hyperglycinemia. The etiology of transient nonketotic hyperglycinemia is presumably related to a delay in the maturation of the glycine cleavage system.<sup><xref ref-type="bibr" rid="bibr6-0883073812441063">6</xref></sup>
</p>
<p>Clinicians should suspect glycine encephalopathy in all seriously ill newborns, especially those presenting profound hypotonia with seizures and/or persistent hiccups.<sup><xref ref-type="bibr" rid="bibr1-0883073812441063">1</xref>,<xref ref-type="bibr" rid="bibr3-0883073812441063">3</xref></sup> Biochemical diagnosis of nonketotic hyperglycinemia begins with the measurement of glycine in cerebrospinal fluid and plasma. A ratio (cerebrospinal fluid/plasma) of 0.08 or more is consistent with typical nonketotic hyperglycinemia (normal values under 0.02),<sup><xref ref-type="bibr" rid="bibr1-0883073812441063">1</xref></sup> although mildly affected patients are reported with ratios of 0.04 to 0.1.<sup><xref ref-type="bibr" rid="bibr6-0883073812441063">6</xref></sup> In some cases, diagnosis requires evaluation of the glycine cleavage system in liver biopsy or cultured lymphoblasts to detect enzyme deficiencies. Demonstration of pathogenic mutations in the genes of glycine cleavage system gives the definitive diagnosis.<sup><xref ref-type="bibr" rid="bibr6-0883073812441063">6</xref></sup>
</p>
<p>In this communication, we present 3 cases of nonketotic hyperglycinemia, 2 typical neonatal and 1 atypical, diagnosed in the Pediatric Hospital of Coimbra, Portugal, and evaluated in Laboratory of Biochemical Genetics, between 2004 and 2010, using ion exchange chromatography, for the screening of aminoacidopathies.</p>
<sec id="section1-0883073812441063">
<title>Case Reports</title>
<sec id="section2-0883073812441063">
<title>Patient 1</title>
<p>JC, a girl born in 2004, is the first child of a healthy nonconsanguineous Portuguese couple. Pregnancy and delivery were uneventful. She was considered healthy up to 2.5 months of age, when multifocal, severe seizures appeared and an epileptic encephalopathy developed, resistant to antiepileptic therapy. Burst suppression pattern was recorded in the electroencephalogram.</p>
<p>Investigation was inconclusive, except for raised glycine levels and cerebrospinal fluid–to–plasma glycine ratio of 0.07 (<xref ref-type="table" rid="table1-0883073812441063">Table 1</xref>), sustained after sodium valproate withdrawal, which reinforced the suspicion of nonketotic hyperglycinemia. Although glycine cleavage system enzymatic activity in the patient’s lymphoblastoid cells was normal: 232 pkat/kg protein (normal = 395 ± 185), a missense mutation p.H83R (homozygosity) in the gene <italic>AMT</italic>, coding for T protein, was found. Both parents are heterozygous for this mutation.</p>
<table-wrap id="table1-0883073812441063" position="float">
<label>Table 1.</label>
<caption>
<p>Glycine Levels of Patients 1, 2, and 3.</p>
</caption>
<graphic alternate-form-of="table1-0883073812441063" xlink:href="10.1177_0883073812441063-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Age</th>
<th>Plasma Gly</th>
<th>CSF Gly</th>
<th>CSF/plasma Gly</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td>6.5 months</td>
<td>8.04</td>
<td>0.59</td>
<td>0.07</td>
</tr>
<tr>
<td rowspan="2">Patient 2</td>
<td>6 days</td>
<td>8.14</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td>7 days</td>
<td>8.51</td>
<td>1.94</td>
<td>0.23</td>
</tr>
<tr>
<td rowspan="2">Patient 3</td>
<td>11 days</td>
<td>5.31</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td>18 days</td>
<td>4.23</td>
<td>0.65</td>
<td>0.15</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0883073812441063">
<p>Abbreviations: CSF, cerebrospinal fluid; Gly, glycine.</p>
</fn>
<fn id="table-fn2-0883073812441063">
<p>Reference values: Plasma glycine (0.61-2.21 mg/dL); cerebrospinal fluid glycine (0-0.06 mg/dL); cerebrospinal fluid–to–plasma glycine ratio (&lt;0.02).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section3-0883073812441063">
<title>Patient 2</title>
<p>GA, a boy born in 2006, is the second child of consanguineous parents (consanguinity coefficient: 1/64). Pregnancy was uneventful and delivery occurred at 35 weeks of gestation by caesarean section due to acute fetal distress, but with no need for ventilatory support. He was admitted in the neonatal intensive care because of poor oral feeding, progressive hypotonia, and apnea. Hiccups ensued and the electroencephalogram showed a burst suppression pattern suggestive of nonketotic hyperglycinemia.</p>
<p>Laboratory evaluation performed at the end of the first week of life detected elevated levels of glycine with a cerebrospinal fluid–to–plasma glycine ratio of 0.23 (<xref ref-type="table" rid="table1-0883073812441063">Table 1</xref>). These results supported the clinical hypothesis of classical nonketotic hyperglycinemia, which was confirmed by the detection of homozygous deletion in the exons 9-15 (c.1156-?_1708+? del) of the P protein coding gene <italic>GLDC</italic>. He presents a severe epileptic encephalopathy resistant to multiple antiepileptic therapies.</p>
</sec>
<sec id="section4-0883073812441063">
<title>Patient 3</title>
<p>MF, a girl born in 2007, is the first child of nonconsanguineous parents. Pregnancy and delivery were uneventful. Hypotonia and feeding difficulties were noticed since birth. At day 6 of life, she was admitted in the neonatal intensive care unit with a severe hypernatremic dehydration and coma. Apart from hypernatremia and respiratory acidosis, the initial biochemical investigation was normal (glucose, lactate, ammonia, 2,4-dinitrophenylhydrazine, blood acylcarnitine profile and septic workup). Despite symptomatic treatment, generalized hypotonia and seizures ensued. Electroencephalogram showed a periodic pattern of burst suppression, which suggested the diagnosis of nonketotic hyperglycinemia.</p>
<p>Diagnosis was achieved by finding elevated glycine levels in plasma and cerebrospinal fluid, with a high ratio (cerebrospinal fluid–plasma) of 0.15 (<xref ref-type="table" rid="table1-0883073812441063">Table 1</xref>). Treatment with vigabatrin reduced the frequency of seizures, but an encephalopathic evolution was noticed. Nonketotic hyperglycinemia was confirmed by the detection of a missense mutation p.H83R (homozygosity) in the gene <italic>AMT</italic>, coding for T protein.</p>
</sec>
</sec>
<sec id="section5-0883073812441063">
<title>Discussion</title>
<p>In the case of a newborn, hypotonia and/or epileptic encephalopathy resistant to conventional therapy should prompt us to suspect an inborn error of metabolism in parallel with more frequent and treatable disorders. Burst suppression or hypsarrhythmic electroencephalographic patterns in any age could also be indicative.</p>
<p>The clinical suspicion of nonketotic hyperglycinemia should lead to the determination of glycine concentrations in plasma and cerebrospinal fluid.</p>
<p>Glycine concentration should be analyzed simultaneously in plasma and cerebrospinal fluid samples, allowing determination of cerebrospinal fluid–to–plasma glycine ratio. Reliable and accurate diagnosis of nonketotic hyperglycinemia is dependent on a careful interpretation of laboratory findings.<sup><xref ref-type="bibr" rid="bibr7-0883073812441063">7</xref></sup> For example, inhibition of the liver glycine cleavage system by organic acids leads to ketotic hyperglycinemia, with ketoacidosis and organic aciduria, but cerebrospinal fluid–to–plasma glycine ratio is normal.<sup><xref ref-type="bibr" rid="bibr1-0883073812441063">1</xref></sup> Sodium valproate, one of the most used antiepileptic drug, inhibits the glycine cleavage system, causing high glycine levels.<sup><xref ref-type="bibr" rid="bibr8-0883073812441063">8</xref>,<xref ref-type="bibr" rid="bibr9-0883073812441063">9</xref></sup> Particular attention should also be given to the possibility of cerebrospinal fluid contamination with blood and patient’s nutritional status.<sup><xref ref-type="bibr" rid="bibr7-0883073812441063">7</xref></sup>
</p>
<p>Glycine may act as an inhibitory neurotransmitter in the spinal cord and brainstem, which is probably associated with apnea and hiccups observed during the disease course. It also may act as an excitatory neurotransmitter in the cortex at the <italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA) receptors, which may explain the epileptic seizures.<sup><xref ref-type="bibr" rid="bibr10-0883073812441063">10</xref></sup>
</p>
<p>Proposed treatments of nonketotic hyperglycinemia include substances that reduce glycine concentration (sodium benzoate or low protein diet), and drugs that antagonize the overstimulation of <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptors in order to prevent excitotoxicity. Ketamine, an <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor antagonist, tried alone or in combination, showed clinical improvement but the results are not consistent.<sup><xref ref-type="bibr" rid="bibr11-0883073812441063">11</xref></sup> However, so far results are not satisfactory. Cases surviving the neonatal period usually progress with severe mental retardation and encephalopathy.</p>
<p>In clinical practice, initial decisions regarding the provision of supportive care for individuals with symptoms pointing to the diagnosis of nonketotic hyperglycinemia, are usually based on the measurement of plasma and cerebrospinal fluid glycine levels. It is important to keep in mind that hyperglycinemia associated with elevated cerebrospinal fluid–to–plasma glycine ratio is not necessarily diagnostic of nonketotic hyperglycinemia.<sup><xref ref-type="bibr" rid="bibr7-0883073812441063">7</xref></sup> It can be associated with a temporary impairment of glycine metabolism in the brain, during periods of encephalopathy, as observed in transient nonketotic hyperglycinemia.<sup><xref ref-type="bibr" rid="bibr12-0883073812441063">12</xref></sup> Therefore, distinguishing the transient from the classic form is important to predict outcome, because most patients with the transient form of nonketotic hyperglycinemia exhibit normal development.<sup><xref ref-type="bibr" rid="bibr13-0883073812441063">13</xref></sup>
</p>
<p>It is also important to understand why patients with nonketotic hyperglycinemia respond differently to the same treatment. Some reports indicate that the poor long-term outcome of classic nonketotic hyperglycinemia is the consequence of irreversible glycine-induced brain damage sustained in the uterus and is little affected by postnatal treatment, regardless of the presence of structural brain abnormalities.<sup><xref ref-type="bibr" rid="bibr1-0883073812441063">1</xref></sup> Other studies indicate that depending on the mutation, the nature and timing of therapeutic intervention are crucial in determining the outcome. To provide a longer term and more accurate prospect of lifelong prognosis, it is important to accumulate further information for genotype-phenotype correlations.<sup><xref ref-type="bibr" rid="bibr14-0883073812441063">14</xref></sup> To date, no reliable associations have been published in cases of nonketotic hyperglycinemia. Mutation screening should be performed in all patients suffering from nonketotic hyperglycinemia (classic neonatal, atypical, and transient) to provide more data, namely, in what concerns therapeutic response.</p>
<p>Most nonketotic hyperglycinemia patients present a P-protein gene defect,<sup><xref ref-type="bibr" rid="bibr2-0883073812441063">2</xref>,<xref ref-type="bibr" rid="bibr5-0883073812441063">5</xref>,<xref ref-type="bibr" rid="bibr11-0883073812441063">11</xref></sup> which is frequently a deletion, such as demonstrated in patient 2. The cases 1 (atypical nonketotic hyperglycinemia) and 3 have a mutation in the protein T coding gene, which is a rare finding in nonketotic hyperglycinemia patients.<sup><xref ref-type="bibr" rid="bibr2-0883073812441063">2</xref>,<xref ref-type="bibr" rid="bibr11-0883073812441063">11</xref>,<xref ref-type="bibr" rid="bibr15-0883073812441063">15</xref></sup></p>
<p>Clinical diagnosis requires confirmation by enzymatic analysis of the glycine cleavage system in liver tissue obtained by invasive biopsy (which is difficult to perform in patients with poor general condition) or mutational analysis of the responsible/involved genes. Both procedures are laborious and they are only performed in a few laboratories worldwide. To reach definitive diagnosis of nonketotic hyperglycinemia, 2 novel laboratory tests are accessible, the <sup><xref ref-type="bibr" rid="bibr13-0883073812441063">13</xref></sup>C-glycine breath test and the multiplex ligation-dependent probe amplification method. As these tests are simple and efficient in the confirmation of the diagnosis of nonketotic hyperglycinemia, biopsy could be avoided. Another advantage of those tests is that the results are achieved faster. Accordingly, its implementation is important in the hospital laboratories.<sup><xref ref-type="bibr" rid="bibr14-0883073812441063">14</xref>,<xref ref-type="bibr" rid="bibr16-0883073812441063">16</xref></sup></p>
<p>Early diagnosis might be important for genetic counseling and for atypical later forms, where early intervention could be beneficial. However, neonatal screening for nonketotic hyperglycinemia would not be suitable since most cases have no blood glycine levels above the cut-off values of 1000 μmol/L, and biochemical diagnosis requires the cerebrospinal fluid and plasma determination at the same time. Diagnosis of nonketotic hyperglycinemia by neonatal screening would implicate a lower cut-off value and consequently an unacceptably high recall rate.<sup><xref ref-type="bibr" rid="bibr17-0883073812441063">17</xref></sup> Although tandem mass spectrometry is a very important tool for newborn screening of inborn errors of metabolism, laboratory analysis of amino acids in physiological fluids, using ion exchange chromatography, continues to be the choice in the laboratory support to the diagnosis of nonketotic hyperglycinemia.<sup><xref ref-type="bibr" rid="bibr17-0883073812441063">17</xref></sup> Glycine evaluation was crucial to the diagnosis in all cases, giving orientation to genetic study, even when the enzymatic glycine cleavage system evaluation was normal as in case 1.</p>
<p>An abnormal cerebrospinal fluid–to–plasma glycine ratio of 0.08, or more, is generally considered diagnostic of nonketotic hyperglycinemia. Patients 2 and 3 (<xref ref-type="table" rid="table1-0883073812441063">Table 1</xref>) are included in this group and clinically correspond to the classic neonatal form with untreatable seizures and encephalopathy. Neonatal form presents a high mortality rate, and survivors present significant neurologic damage, including severe mental retardation.<sup><xref ref-type="bibr" rid="bibr1-0883073812441063">1</xref></sup> There is some controversy over if cerebrospinal fluid–to–plasma glycine ratio is correlated with prognosis in classic nonketotic hyperglycinemia. Dinopoulos et al indicate that the atypical form appears to present cognitive impairment associated with an elevated glycine ratio (cerebrospinal fluid–plasma).<sup><xref ref-type="bibr" rid="bibr11-0883073812441063">11</xref></sup></p>
<p>There are also several reports of patients with biochemical, enzymatic, and genetic evidence of nonketotic hyperglycinemia, but a less severe clinical presentation,<sup><xref ref-type="bibr" rid="bibr11-0883073812441063">11</xref></sup> such as the one found in patient 1.</p>
<p>The 3 patients presented are probably the only nonketotic hyperglycinemia cases diagnosed in Central Portugal during that period of time (2004-2010), incidence: 1:47 455; prevalence: 1:782 951. Among the 1263 patients investigated for amino acid profile in Laboratory of Biochemical Genetics between 2004 and 2010, three children presented abnormalities strongly indicative of glycine encephalopathy (frequency: 0.23%).</p>
<p>Amino acid analysis, in the plasma and cerebrospinal fluid, presents diagnostic value for classic nonketotic hyperglycinemia, but it also should be performed in suspected cases of atypical and transient forms.<sup><xref ref-type="bibr" rid="bibr2-0883073812441063">2</xref></sup> This technique should also be performed in children with seizures, development delay, behavior problems, and uncoordinated movements, because it could help in diagnosis, although cerebrospinal fluid–to–plasma glycine ratio may present greater variability.</p>
<p>An early diagnosis, though it does not change the disease course because there is no effective treatment, allows proper genetic counseling, with the possibility of prenatal diagnosis.<sup><xref ref-type="bibr" rid="bibr1-0883073812441063">1</xref>,<xref ref-type="bibr" rid="bibr6-0883073812441063">6</xref></sup> Another benefit of diagnosis is that having a definite diagnosis with this phenotype prevents further unnecessary investigations for other genetic or metabolic etiologies.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgment</title>
<p>The authors are grateful to Prof M. O. Rolland and Dr C. Vianey-Saban, Service de Biochimie Pediatrique, Hôpital Debrousse Lyon, for enzyme and DNA studies.</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn1a-0883073812441063"><label>Author Contributions</label>
<p>CV gathered all the data presented in the paper. CV and MS performed the biochemical analysis of amino acids. PG, CR, and RH participated in the clinical investigation. PG and LD provided metabolic consultation. LD conducted the clinical investigation, and along with MG, supervised the writing of the paper. MG was responsible for the work in the Laboratory of Biochemical Genetics and conducted the laboratory investigation.</p>
</fn>
<fn fn-type="conflict" id="fn1-0883073812441063"><label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0883073812441063"><label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="other" id="fn2a-0883073812441063"><label>Ethical Approval</label>
<p>The study was conducted according to the ethic issues required in our institutions.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073812441063">
<label>1</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Hamosh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>MV</given-names>
</name>
</person-group>. <article-title>Nonketotic hyperglycinemia</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Scriver</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Beaudet</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Sly</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Valle</surname>
<given-names>D</given-names>
</name>
</person-group>, eds. <source>The Metabolic and Molecular Bases of Inherited Disease</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>McGraw-Hill</publisher-name>; <year>2001</year>:<fpage>2065</fpage>–<lpage>2078</lpage>.</citation>
</ref>
<ref id="bibr2-0883073812441063">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kikuchi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Motokawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hiraga</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Glycine cleavage system: reaction mechanism, physiological significance, and hyperglycinemia</article-title>. <source>Proc Jpn Acad Ser B Phys Biol Sci</source>. <year>2008</year>;<volume>84</volume>:<fpage>246</fpage>–<lpage>263</lpage>.</citation>
</ref>
<ref id="bibr3-0883073812441063">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Von Wendt</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hirvasniemi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Similä</surname>
<given-names>S.</given-names>
</name>
</person-group> <article-title>Nonketotic hyperglycinemia. A genetic study of 13 Finnish families</article-title>. <source>Clin Genet</source>. <year>1979</year>;<volume>15</volume>:<fpage>411</fpage>–<lpage>417</lpage>.</citation>
</ref>
<ref id="bibr4-0883073812441063">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Applegarth</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Toone</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Lowry</surname>
<given-names>RB</given-names>
</name>
</person-group>. <article-title>Incidence of inborn errors of metabolism in British Columbia, 1969-1996</article-title>. <source>Pediatrics</source>. <year>2000</year>;<volume>105</volume>: <fpage>e10</fpage>.</citation>
</ref>
<ref id="bibr5-0883073812441063">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flusser</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Korman</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Matsubara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Galil</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kure</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Mild glycine encephalopathy (NKH) in a large kindred due to a silent exonic GLDC splice mutation</article-title>. <source>Neurology</source>. <year>2005</year>;<volume>64</volume>:<fpage>1426</fpage>–<lpage>1430</lpage>.</citation>
</ref>
<ref id="bibr6-0883073812441063">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Applegarth</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Toone</surname>
<given-names>JR</given-names>
</name>
</person-group>. <article-title>Nonketotic hyperglycinemia (glycine encephalopathy): laboratory diagnosis</article-title>. <source>Mol Genet Metab</source>. <year>2001</year>;<volume>74</volume>:<fpage>139</fpage>–<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr7-0883073812441063">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korman</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Gutman</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Pitfalls in the diagnosis of glycine encephalopathy (non-ketotic hyperglycinemia)</article-title>. <source>Dev Med Child Neurol</source>. <year>2002</year>;<volume>44</volume>:<fpage>712</fpage>–<lpage>720</lpage>.</citation>
</ref>
<ref id="bibr8-0883073812441063">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mortensen</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Kolvraa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Inhibition of the glycine cleavage system: hyperglycinemia and hyperglycinuria caused by valproic acid</article-title>. <source>Epilepsia</source>. <year>1980</year>;<volume>21</volume>:<fpage>563</fpage>–<lpage>568</lpage>.</citation>
</ref>
<ref id="bibr9-0883073812441063">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morrison</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Sankar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shields</surname>
<given-names>WD</given-names>
</name>
</person-group>. <article-title>Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia</article-title>. <source>Pediatr Neurol</source>. <year>2006</year>;<volume>35</volume>:<fpage>356</fpage>–<lpage>358</lpage>.</citation>
</ref>
<ref id="bibr10-0883073812441063">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohya</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ochi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mizutani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hayakawa</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>K.</given-names>
</name>
</person-group> <article-title>Nonketotic hyperglycinemia: Treatment with NMDA antagonist and consideration of neuropathogenesis</article-title>. <source>Pediatr Neurol</source>. <year>1991</year>;<volume>7</volume>:<fpage>65</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr11-0883073812441063">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinopoulos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Matsubara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kure</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Atypical variants of nonketotic hyperglycinemia</article-title>. <source>Mol Genet Metab</source>. <year>2005</year>;<volume>86</volume>:<fpage>61</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr12-0883073812441063">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aburahma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Khassawneh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Griebel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Pitfalls in measuring cerebrospinal fluid glycine levels in infants with encephalopathy</article-title>. <source>J Child Neurol</source>. <year>2011</year>;<volume>26</volume>:<fpage>703</fpage>–<lpage>706</lpage>.</citation>
</ref>
<ref id="bibr13-0883073812441063">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aliefendioglu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Aslan</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Coskun</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dursun</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cakmak</surname>
<given-names>FN</given-names>
</name>
<name>
<surname>Kesimer</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Transient nonketotic hyperglycinemia: two case reports and literature review</article-title>. <source>Pediatr Neurol</source>. <year>2003</year>;<volume>28</volume>:<fpage>151</fpage>–<lpage>155</lpage>.</citation>
</ref>
<ref id="bibr14-0883073812441063">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Susuzi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kure</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Oota</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hino</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fukuda</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Nonketotic hyperglycinemia: proposal of a diagnosis and treatment strategy</article-title>. <source>Pediatr Neurol</source>. <year>2010</year>;<volume>43</volume>:<fpage>221</fpage>–<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr15-0883073812441063">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanno</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hutchin</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kamada</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group> <article-title>Genomic deletion within GLDC is a major cause of non-ketotic hyperglycinaemia</article-title>. <source>J Med Genet</source>. <year>2007</year>;<volume>44</volume>:<fpage>e69</fpage>.</citation>
</ref>
<ref id="bibr16-0883073812441063">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kure</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Two novel laboratory tests facilitating diagnosis of glycine encephalopathy (nonketotic hyperglycinemia)</article-title>. <source>Brain Dev</source>. <year>2011</year>;<volume>33</volume>:<fpage>753</fpage>–<lpage>757</lpage>.</citation>
</ref>
<ref id="bibr17-0883073812441063">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Wiley</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Carpenter</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wilcken</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Non-ketotic hyperglycinemia is usually not detectable by tandem mass spectrometry newborn screening</article-title>. <source>Mol Genet Metab</source>. <year>2007</year>;<volume>90</volume>:<fpage>446</fpage>–<lpage>448</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>